Patents Issued in March 23, 2017
  • Publication number: 20170079988
    Abstract: The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).
    Type: Application
    Filed: October 13, 2016
    Publication date: March 23, 2017
    Inventors: Balazs ALBRECHT, Michael AVEN, Janine LAMAR, Ingo LANG
  • Publication number: 20170079989
    Abstract: The methods using associated formulations for intra-articular local delivery to treat an afflicted joint, for example, to treat osteoarthritis. Some methods deliver anti-inflammatory agents and angiogenesis inhibitors, and can include sensitizing agents for one or both. Formulations can include hyaluronic acid, a therapeutic solvent, and drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The carrier can include hydrophobic sugar nano-particles, which can resist degradation and provide extended cushioning. The excipient or polymer can be used to manipulate release rates and to increase drug retention to the affected region.
    Type: Application
    Filed: August 31, 2016
    Publication date: March 23, 2017
    Inventor: Thomas Q. Dinh
  • Publication number: 20170079990
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Publication number: 20170079991
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Publication number: 20170079992
    Abstract: The invention provides, inter alia, methods of treating a disorder characterized by excessive metakaryotic stem cell growth by a combination metakaryocidal therapy. Also encompassed by the present invention are preventative methods comprising the administration of a metakaryocidal or metakayrostatic therapeutic agent.
    Type: Application
    Filed: March 17, 2015
    Publication date: March 23, 2017
    Inventors: William G. Thilly, Elena V. Gostjeva
  • Publication number: 20170079993
    Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
    Type: Application
    Filed: October 3, 2016
    Publication date: March 23, 2017
    Applicant: Arctic Nutrition AS
    Inventors: Hogne HALLARAKER, Jan REMMEREIT, Alvin BERGER
  • Publication number: 20170079994
    Abstract: The disclosure relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma. The disclosure also relates to methods of treating conditions using prodrugs of vitamin K2.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Inventors: Mona Moller, Marcel Sandberg, Inger Reidun Aukrust
  • Publication number: 20170079995
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventor: Herriot Tabuteau
  • Publication number: 20170079996
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions such as arthritis.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20170079997
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20170079998
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions such as arthritis.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20170079999
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Terrence C. DAHL, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLIYAI, Taiyin YANG
  • Publication number: 20170080000
    Abstract: A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Donald F. Hodgson, Crispin G.S. Eley
  • Publication number: 20170080001
    Abstract: Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
    Type: Application
    Filed: August 25, 2016
    Publication date: March 23, 2017
    Inventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
  • Publication number: 20170080002
    Abstract: The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded ?-linked galactose residues; b) providing a sialic acid donor having (?2-3)-sialylated O-glycans; c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and d) isolating from said enzyme reaction mixture a fraction comprising at least 20 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Applicant: RIJKSUNIVERSITEIT GRONINGEN
    Inventors: Erik SALLOMONS, Maarten Hotse WILBRINK, Peter SANDERS, Johannis Paulus KAMERLING, Catherina Anna van VUURE, Johannes Adrianus HAGE
  • Publication number: 20170080003
    Abstract: The present invention relates to a formulation of thermosensitive liposomes, and more specifically to a formulation of liposomes comprising phospholipids and a surface active agent, wherein the liposomes support long term storage at temperatures less than or equal to about 8° C., control degradate formation to maximize product potency and release their contents at mild hyperthermic temperatures. Methods of making formulations are also described.
    Type: Application
    Filed: November 29, 2016
    Publication date: March 23, 2017
    Inventors: Robert A. Reed, Daishui SU
  • Publication number: 20170080004
    Abstract: The invention provides an agent for treating depression, which contains N-acetyl-D-mannosamine, and a pharmaceutical composition for treating depression, which contains an effective amount of N-acetyl-D-mannosamine and a carrier acceptable as a medicament.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Kunio SHIOTA, Shintaro YAGI, Koji HAYAKAWA, Mitsuko TAKAMORI, Takefumi KIKUSUI, Yukishige ITO, Yasuharu SAKAMOTO, Hideharu SETO
  • Publication number: 20170080005
    Abstract: The present invention relates to a synergistic composition which comprises (a) phlorizin, and (b) at least one further defined inhibitor of the enzyme lactase-phlorizin hydrolase. In particular, the present invention relates to such a composition for the treatment and/or prophylaxis of a hyperglycemic disease such as obesity, diabetes or a secondary disease associated with diabetes. The invention further relates to the use of such a composition for preparing a pharmaceutical composition, a dietary foodstuff and/or a food supplement. The invention further relates to pharmaceutical compositions, dietetic foods and food supplements which comprise a composition according to the present invention.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Inventor: Henning Vollert
  • Publication number: 20170080006
    Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 23, 2017
    Applicant: Kardiatonos, Inc.
    Inventors: Josefino B. Tunac, Kenneth I. Kohn
  • Publication number: 20170080007
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Application
    Filed: August 30, 2016
    Publication date: March 23, 2017
    Inventor: Jin Q. CHENG
  • Publication number: 20170080008
    Abstract: The present invention relates to stable pharmaceutical compositions of sofosbuvir or a pharmaceutically acceptable salt thereof comprising at least one pharmaceutically acceptable excipient, in the form of immediate release tablets, to a process for the manufacture of said stable pharmaceutical compositions and to uniform pharmaceutical batches of said immediate release tablets.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 23, 2017
    Inventor: Sergio Hidalgo ARROYO
  • Publication number: 20170080009
    Abstract: F10 is an oligonucleotide based on the thymidylate synthase (TS) inhibitory 5-fluorouracil (5-FU) metabolite, 5-fluoro-2?-deoxyuridine-5?-O-monophosphate. The activity of F10 against preclinical ALL models was determined. F10 treatment resulted in robust induction of apoptosis that could not be equaled by 100 fold more 5-FU. F10 was more potent than Ara-C and doxorubicin against a panel of murine and human ALL cells with an average IC50 value of 1.48 nM (range 0.07 to 5.4 nM). F10 was more than 1000 times more potent than 5-FU. In vivo, F10 treatment resulted in a significant increase in survival in 2 separate syngeneic ALL mouse models and 3 separate xenograft models. F10 also protected mice from leukemia-induced weight loss. In ALL cells made resistant to Ara-C F10 remained highly active in vitro and in vivo. Using labeled F10, it was determined that uptake by the ALL cell lines DG75 and SUP-B15 was rapid and had a profound temperature dependence.
    Type: Application
    Filed: May 14, 2015
    Publication date: March 23, 2017
    Inventors: William H. Gmeiner, Timothy S. Pardee
  • Publication number: 20170080010
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 23, 2017
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Publication number: 20170080011
    Abstract: Disclosed is use of nicotinamide adenine dinucleotide (NADH) and ?-nicotinamide mononucleotide (NMN) in the preparation of drugs or health-care products for treating Parkinson's disease, in which ?-NADH and ?s-NMN are produced enzymatically.
    Type: Application
    Filed: December 3, 2015
    Publication date: March 23, 2017
    Inventors: Rongzhao FU, Qi ZHANG
  • Publication number: 20170080012
    Abstract: Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventor: Massimo IACOBELLI
  • Publication number: 20170080013
    Abstract: Disclosed are compositions comprising hydrocortisone acetate and a biopolymer, chitosan, in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a buffering agent, and water. The compositions disclosed herein are suitable for the treatment of dermatological conditions including but not limited to healing wounds and treatment of dermatitis.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Sular Subramaniam Vanangamudi, Srinivasan Murali, Srinivasan Madhavan
  • Publication number: 20170080014
    Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
  • Publication number: 20170080015
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 23, 2017
    Inventors: Mark L. HEIMAN, Dean P. STULL, Justin W. PENO
  • Publication number: 20170080016
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 23, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170080017
    Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 23, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170080018
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 23, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170080019
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with neuropathic pain, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 23, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170080020
    Abstract: The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as Staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a site of infection, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 23, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170080021
    Abstract: The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 23, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170080022
    Abstract: A hydrogen-containing composition for ingestion or topical use and method of producing the hydrogen-containing composition are provided. The composition includes a carrier liquid and molecular hydrogen. The concentration of molecular hydrogen in the carrier liquid is greater than 3 ppm.
    Type: Application
    Filed: May 12, 2015
    Publication date: March 23, 2017
    Inventor: Gail Levy
  • Publication number: 20170080023
    Abstract: A composition and an article of manufacture providing relief of indigestion, heartburn, GERD and some hangovers. The composition is an oleophilic colloidal suspension of a finely ground powder of USP calcium carbonate suspended in a usually tasteless edible oil; wherein the suspension has a weight ratio range of oil to calcium carbonate that is from about 1.0 (oil) to 0.25 (calcium carbonate) to about 1.0 (oil) to 2.2 (calcium carbonate); and a single dose has a calcium carbonate weight range from about 200 mg to about 1000 mg. The composition can include other foods and additives so that it may be used and dispensed in a plurality of delivery systems and foods. The oleophilic colloidal suspension can be dispensed as a soft-gel.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 23, 2017
    Inventors: Ofer Agam, Francis Rhett Brockington
  • Publication number: 20170080024
    Abstract: An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium bicarbonate and Sodium carbonate), Potassium (as potassium bicarbonate), Salt (as sodium chloride), Aloe Vera, Chamomile (as matricaria recutita), Honey, and/or Stevia Leaf extract. The anhydrous composition may further comprise Citric Acid, Sorbitol, Natural flavor, Wheat Germ Oil, and/or Magnesium Oxide.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Timothy P. O'Connor, Janet January Lockard-O'Connor
  • Publication number: 20170080025
    Abstract: An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium bicarbonate and Sodium carbonate), Potassium (as potassium bicarbonate), Salt (as sodium chloride), Aloe Vera, Chamomile (as matricaria recutita), Honey, and/or Stevia Leaf extract. The anhydrous composition may further comprise Citric Acid, Sorbitol, Natural flavor, Wheat Germ Oil, and/or Magnesium Oxide.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Timothy P. O'Connor, Janet January Lockard-O'Connor
  • Publication number: 20170080026
    Abstract: A claimed invention relates to the field of medicine or biology, namely the methods using nanotechnology objects, in particular colloidal solutions of gold nanoparticles which demonstrate a strongly marked effect on cellular proteins and can be used to restore the contractile function of mammalian vascular smooth muscle cells. Further, the invention relates to medicinal products which comprise gold nanoparticles and may be used for remote opening of voltage-gated ion channels in mammalian vascular smooth muscle cells. A method for remote opening of voltage-gated ion channels in mammalian vascular smooth muscle cells comprises extracellular application of a colloidal solution of gold nanoparticles in population of mammalian vascular smooth muscle cells.
    Type: Application
    Filed: September 8, 2016
    Publication date: March 23, 2017
    Inventors: Anatoly I. Soloviev, Oleksandr V. Zholos, Irina V. Ivanova, Tetiana V. Novokhatska, Oleksandr L. Stroyuk, Oleksandra Ye. Raievska, Igor M. Parneta, Volodymyr S. Yefanov
  • Publication number: 20170080027
    Abstract: Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.
    Type: Application
    Filed: October 12, 2015
    Publication date: March 23, 2017
    Inventors: Yeon S. AHN, Wenche JY, Lawrence L. HORSTMAN
  • Publication number: 20170080028
    Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventor: ANTOINE TURZI
  • Publication number: 20170080029
    Abstract: The invention relates to immuno-modulatory progenitor (IMP) cells and their use in therapy.
    Type: Application
    Filed: June 9, 2015
    Publication date: March 23, 2017
    Inventors: Ajan REGINALD, Martin John EVANS, Sabena SULTAN, Lee Phillip CHAPMAN
  • Publication number: 20170080030
    Abstract: The present invention encompasses the use of adipose tissue derived cells, or conditioned medium of such cells, to treat and prevent vascular related injuries, diseases, disorders, and conditions such as diabetic retinopathy, where, in one aspect, pericytes such as retinal pericytes have been lost or damaged. The present application further discloses compositions and methods useful for enhancing the function and activity of the adipose tissue derived cells in the treatment and prevention of injuries, diseases, disorders, and conditions including the use of TGF? to condition the cells to enhance their activity.
    Type: Application
    Filed: March 17, 2015
    Publication date: March 23, 2017
    Inventors: Shayn Peirce-Cottler, Paul Andrew Yates, Thomas A. Mendel
  • Publication number: 20170080031
    Abstract: Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.
    Type: Application
    Filed: May 7, 2015
    Publication date: March 23, 2017
    Inventors: Senlin LI, Robert A. Clark, Cang CHEN
  • Publication number: 20170080032
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 23, 2017
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20170080033
    Abstract: Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Trophic factors and other agents secreted by the progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells such as photoreceptor cells are also disclosed.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Applicant: Janssen Biotech, Inc.
    Inventors: Ian R. Harris, Jing Cao, Nadine Dejneka
  • Publication number: 20170080034
    Abstract: The invention relates to a pharmaceutical or probiotic composition comprising at least one Lactobacillus strain with intestinal tropism, especially selected from the species Lactobacillus plantarum, Lactobacillus fermentum and Lactobacillus casei, used to stimulated juvenile growth in cases of malnutrition especially characterised by a protein deficiency. The strains can be selected from a vinegar fly model and/or a mouse model. The invention also relates to a method for probiotic treatment using said composition.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Inventors: François LEULIER, Gilles STORELLI, Martin SCHWARZER, Maria Elena MARTINO
  • Publication number: 20170080035
    Abstract: The present invention provides a pharmaceutical composition for treating rotavirus and/or respiratory syncytial virus infection and a method for preparing the same; wherein said pharmaceutical composition comprises a therapeutically effective amount of Spirulina extract and a pharmaceutically acceptable carrier. The Spirulina extract used in the present invention is extracted at a low temperature by the following steps: (a) adding an organic Spirulina powder into a hypotonic buffer solution and mixed well to obtain a mixture; (b) freezing the mixture from step (a) overnight at a temperature lower than 0° C.; (c) thawing the mixture from step (b); (d) separating and purifying the mixture from step (c) by a separator, and collecting blue fractions; and (e) spray drying the blue fractions from step (d).
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventors: Chuang Chun CHIUH, Chun Nan LEE, Chun Ting CHENG
  • Publication number: 20170080036
    Abstract: The present invention relates to a complex of PPSA or PSPA polymer and a virus, and a pharmaceutical composition including the same. According to the present invention, when a polymer-virus complex formed using PPSA or PSPA polymer is used, transduction efficiency thereof to cells may be enhanced, an excellent therapeutic effect may thus be obtained when used as a pharmaceutical composition, and, therefore, the pharmaceutical agent may be useful as a therapeutic agent.
    Type: Application
    Filed: August 12, 2016
    Publication date: March 23, 2017
    Inventors: Chae Ok YUN, Kasala DAYANANDA
  • Publication number: 20170080037
    Abstract: Compositions for appetite control and/or regulation or loss of weight are described. The described compositions comprise a unique combination of ingredients, the combination including at least botanical substances, amino acids, and one or more metals, and may comprise and in some embodiments do further comprise one or more vitamins and/or caffeine. The compositions are taken by mouth and provide a multi-targeted approach for the regulation and control of appetite for subjects taking the composition. The composition is preferably taken before a meal. A recommended dose includes at least one dose of the described composition per day.
    Type: Application
    Filed: September 17, 2015
    Publication date: March 23, 2017
    Inventor: Sue Ann Alter